Treatment of Huntington's chorea with bromocriptine.
作者： Lodovico Frattola , Maria Grazia Albizzati , Pier Franco Spano , Marco Trabucchi
DOI: 10.1111/J.1600-0404.1977.TB01407.X
关键词: Gait 、 Bromocriptine 、 Abnormal involuntary movement 、 Disease severity 、 Physical medicine and rehabilitation 、 Dopamine receptor 、 Crossover study 、 Spatial behavior 、 Endocrinology 、 Chorea 、 Medicine 、 Internal medicine
摘要: The authors tested the effects of 2-Br-ergocriptine (bromocriptine, CB-154), a drug which exerts mixed agonist-antagonist activity on dopaminergic receptors, in 12 patients with Huntington Chorea double-blind crossover trial. This treatment significantly reduced abnormal involuntary movements and disease severity most patients. Subjects who were slightly disabled showed better response than ones more severe degrees disability.
elsevier.com
sci-hub.se 参考文章(17)
André Barbeau, Recent Progress: Progress in Understanding Huntington’s Chorea Canadian Journal of Neurological Sciences. ,vol. 2, pp. 81- 85 ,(1975) , 10.1017/S0317167100020047
Eduardo S. Tolosa, Sheldon B. Sparber, Apomorphine in Huntington's chorea: clinical observations and theoretical considerations. Life Sciences. ,vol. 15, pp. 1371- 1380 ,(1974) , 10.1016/0024-3205(74)90319-1
Stuart R. Snider, Cheryl Hutt, Bruce Stein, A. L. N. Prasad, Stanley Fahn, Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover. Journal of Pharmacy and Pharmacology. ,vol. 28, pp. 563- 566 ,(2011) , 10.1111/J.2042-7158.1976.TB02796.X
Patrick L. McGeer, Edith G. McGeer, Neurotransmitter synthetic enzymes Progress in Neurobiology. ,vol. 2, pp. 69- 117 ,(1973) , 10.1016/0301-0082(73)90007-5
J D Parkes, C D Marsden, I Donaldson, A Galea-Debono, J Walters, G Kennedy, P Asselman, Bromocriptine treatment in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. ,vol. 39, pp. 184- 193 ,(1976) , 10.1136/JNNP.39.2.184
M. Trabucchi, P.F. Spano, G.C. Tonon, L. Frattola, Effects of bromocriptine on central dopaminergic receptors. Life Sciences. ,vol. 19, pp. 225- 232 ,(1976) , 10.1016/0024-3205(76)90394-5
Ronald Kartzinel, Paul Teychenne, MarjorieM. Gillespie, Mark Perlow, AndreaC. Gielen, DorisA. Sadowsky, DonaldB. Calne, BROMOCRIPTINE AND LEVODOPA (WITH OR WITHOUT CARBIDOPA) IN PARKINSONISM The Lancet. ,vol. 308, pp. 272- 275 ,(1976) , 10.1016/S0140-6736(76)90728-5
R. KARTZINEL, I. SHOULSON, D. B. CALNE, Studies with bromocriptine: III. Concomitant administration of caffeine to patients with idiopathic parkinsonism. Neurology. ,vol. 26, pp. 741- 741 ,(1976) , 10.1212/WNL.26.8.741
Anddré Barbeau, Kazuya Ando, DOPAMINE AND HUNTINGTON'S CHOREA The Lancet. ,vol. 305, pp. 987- ,(1975) , 10.1016/S0140-6736(75)92060-7
A.M. JOHNSON, D.M. LOEW, J.M. VIGOURET, Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA. British Journal of Pharmacology. ,vol. 56, pp. 59- 68 ,(1976) , 10.1111/J.1476-5381.1976.TB06959.X